No Benefit to Add-on Antiplatelet Therapy in Moderate Covid-19

Press/Media: Public Engagement › Popular

Description

Adding P2Y12 inhibition to an anticoagulant offered no additional benefit in moderately ill patients with Covid-19, ACTIV-4a researchers reported. ... or add-on aspirin added to standard thromboprophylaxis or anticoagulant therapy (RECOVERY), noted Hugo ten Cate, MD, PhD, of Maastricht University Medical Center in the Netherlands, and co-authors ...

Period19 Jan 2022

Media coverage

1

Media coverage

  • TitleNo Benefit to Add-on Antiplatelet Therapy in Moderate Covid-19
    Degree of recognitionInternational
    Media name/outletBreakingMED
    Media typeOnline
    Country/TerritoryUnited States
    Date19/01/22
    DescriptionAdding P2Y12 inhibition to an anticoagulant offered no additional benefit in moderately ill patients with Covid-19, ACTIV-4a researchers reported. ... or add-on aspirin added to standard thromboprophylaxis or anticoagulant therapy (RECOVERY), noted Hugo ten Cate, MD, PhD, of Maastricht University Medical Center in the Netherlands, and co-authors ...
    Producer/AuthorShalmali Pal
    URLhttps://breakingmed.org/article.html?articleid=85659
    PersonsHugo ten Cate
View all 1
View less

Keywords

  • Berger’s group
  • CV organ support
  • Cate’s group
  • P2Y12 inhibitor
  • adaptive randomized clinical trial
  • additional benefit
  • agent arm
  • authors
  • composite primary outcome
  • conventional prophylaxis doses